en · de · es
sr9009-notes.peptides1004.com › Guide › Mechanism And Preclinical Findings — Reference Sheet

Mechanism And Preclinical Findings — Reference Sheet

By Editorial Desk · published 2026-05-31 · last reviewed 2026-07-11 · Guide

storage stability comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2026-07-11. Numbers and descriptions here follow the published literature rather than marketing material.

Mechanism and Preclinical Findings

SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.

Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.

The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.

Analytical Detection and Storage

Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.

Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.

Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic REV-ERB agonistSmall molecule; not a steroid or peptide.
Primary targetsNR1D1 and NR1D2Also known as REV-ERBα and REV-ERBβ.
Studied routesIntraperitoneal in rodentsOral bioavailability in humans is not established.
Human approvalNo approved therapeutic indicationNo recognized clinical use.
Key uncertaintyHuman physiological effectsPreclinical findings may not translate.

Identity, Handling, and Regulation

Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.

Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.

Related pages on this site

Background and Mechanism

Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.

At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.

Notes from published material

== Medical use == Tapentadol is used for the treatment of moderate to severe pain for both acute (following e.g. injury or surgery) and chronic musculoskeletal pain. It is also specifically indicated for controlling the pain of diabetic neuropathy when around-the-clock opioid medication is required. Extended-release formulations of tapentadol are not indicated for use in the management of acute pain and are instead indicated only for the relief of severe, disabling pain, that is long-term in nature and cannot be controlled by any other pharmacological means. Tapentadol is pregnancy category C. There are no adequate and well-controlled studies of tapentadol in pregnant women, and tapentadol is not recommended for use in women during and immediately prior to labor and delivery. There are no adequate and well-controlled studies of tapentadol in children.

=== Distribution === Met-enkephalin is found mainly in the adrenal medulla and throughout the central nervous system (CNS), including in the striatum, cerebral cortex, olfactory tubercle, hippocampus, septum, thalamus, and periaqueductal gray, as well as the dorsal horn of the spinal cord. It is also present in the periphery, notably in some primary afferent fibers that innervate the pelvic viscera.

Improving metabolism (improving insulin sensitivity, inhibiting de novo lipogenesis, or increasing fatty acid oxidation). Metabolic modulators tested in MASH include glucagon-like peptide-1 receptor agonists (GLP-1 agonists), GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) or glucagon co-agonists and thyromimetics. Some of these drugs may treat MASFLD by significantly reducing body weight. Reducing inflammation, for example reducing oxidative stress and hepatocyte death. These drugs, such as chemokine antagonists, anti-apoptotics, vascular adhesion protein-1 inhibitors, and c-Jun N-terminal kinase inhibitors, have not shown benefit. "Gut-liver axis targets" that either change a person's microbiome, or act on bile acids Anti-fibrotic drugs, such as fibroblast growth factor analogues, which have largely not met their endpoints Other treatments such as farnesoid X receptor (FXR) agonists, peroxisome proliferator-activated receptor (PPAR) agonists, and ASK1 (apoptosis signal-regulating kinase 1) inhibitors may improve MASFLD by multiple mechanisms simultaneously.

Sources: en.wikipedia.org

Further detail

Acetylcysteine was patented in 1960 as a mucolytic agent. In the 1960s, it was used for managing the mucous symptoms of illnesses including cystic fibrosis, asthma, and chronic bronchitis, as well as other uses, such as a chelating agent in gold therapy. In the late 1960s, the popularity of acetaminophen led to an increase in overdose hepatotoxicity. In 1974, it was discovered that the mechanism was oxidation via cytochrome P450, and administering glutathione-like reducing agents, such as IV cysteine, or oral methionine, were successful in preventing hepatotoxicity. In the US, the then-common formulation of NAC was not certified as pyrogen-free, and thus not approved for IV use. The producer, Mead Johnson, was unwilling to take the expense of certification. In 1977, there was the first case report of oral NAC preventing acetaminophen overdose hepatoxicity in the US. Meanwhile, in the UK, IV NAC (trade name, Parvolex) was found to be more effective and has less side effect than IV cysteamine (associated with a "general feeling of misery") or methionine. There was a dispute concerning whether the oral NAC and the IV NAC is more effective, with the conclusion reached in 1999, that they are roughly equally effective. Another producer finally obtained approval for the IV form of NAC (trade name, Acetadote) in the US in 2004. Amazon removed acetylcysteine for sale in the US in 2021, due to claims by the Food and Drug Administration (FDA) of it being classified as a drug rather than a supplement.

Cyanogen bromide is the inorganic compound with the formula BrCN. It is a colorless solid that is widely used to modify biopolymers, fragment proteins and peptides (cuts the C-terminus of methionine), and synthesize other compounds. The compound is classified as a pseudohalogen.

Slavery is the ownership of a person as property, especially in regard to their labour. It is an economic phenomenon and its history resides in economic history. Slavery typically involves compulsory work, with the slave's location of work and residence dictated by the party that holds them in bondage. Enslavement is the placement of a person into slavery, and the person is called a slave or an enslaved person. Many historical cases of enslavement occurred as a result of breaking the law, becoming indebted, suffering a military defeat, or exploitation for cheaper labor; other forms of slavery were instituted along demographic lines such as race or sex. Slaves would be kept in bondage for life, or for a fixed period of time after which they would be granted freedom. Although slavery is usually involuntary and involves coercion, there are also cases where people voluntarily enter into slavery to pay a debt or earn money due to poverty. In the course of human history, slavery was a common feature of civilization, and existed in most societies throughout history, but it is now outlawed in every country in the world except as a punishment for a crime. In general there were two types of slavery throughout human history: domestic and productive. In chattel slavery, the slave is legally rendered the personal property (chattel) of the slave owner. In economics, the term de facto slavery describes the conditions of unfree labour and forced labour that most slaves endure.

Specimens may also be stored using nested protective packaging systems; one example is the "Swedish method", in which paper envelopes are placed in cardboard boxes and then in larger rigid boxes. The Muséum national d'histoire naturelle has described varied packaging approaches in its collections, including boxes, envelopes, bound herbarium boards, and specialised slide collections for microscopic groups. The general aim of curation is to preserve both the physical structure needed for morphological study and the chemical integrity required for molecular analysis. Drying techniques vary: heat drying at 40–50 °C (104–122 °F) typically favours the retention of microscopic structures, while freeze-drying preserves colour and macroscopic form at the cost of increased fragility. For damp or woody material, low-temperature drying with high ventilation helps prevent further fungal growth and may limit DNA damage. Although liquid preservation in alcohol or formalin maintains a specimen's three-dimensional shape, it often results in colour loss and DNA degradation. While liquid preservation in glass containers maintains a specimen's three-dimensional shape, the choice of preservation method involves trade-offs between physical integrity and the suitability of the material for future DNA analysis. Because many fungi change markedly in appearance during drying, collecting practice has long included recording features of the living fungus through notes and images; the research value of a specimen is increased when such derivative documentation remains linked to the specimen record.

Sources: en.wikipedia.org

Background from the literature

Subsequently, several ministers from the Bhumjaithai Party, the second-largest party in the ruling coalition, resigned, leading to the party's withdrawal from the coalition government, citing harm to national dignity. The episode sparked protests and calls for her resignation. Following the leak, Paetongtarn responded swiftly but was unable to fully contain the political fallout. At a press conference on 18 June 2025, she confirmed the authenticity of the recording before defending her remarks as part of an "off-the-record approach in a private conversation" and a "negotiation strategy" intended to defuse tensions with Hun Sen, who was reportedly angered by comments from a senior Thai military officer. Paetongtarn accused Hun Sen of breaching diplomatic trust and implied that the leak had been orchestrated to bolster his domestic popularity. She announced that she would refrain from future private discussions due to "trust issues". Paetongtarn denied any rift with the Thai military, stating that her remarks had been misinterpreted and that she had contacted the commander in question to clarify the context. In response, the Bhumjaithai Party issued a statement condemning her conduct as damaging to the country's reputation, alleging it had caused "the country, people, and army to lose dignity". The party's withdrawal from the governing coalition left the Pheu Thai–led government with a slim parliamentary majority, placing its stability in jeopardy.

Phytoplankton, also known as microscopic algae. Free-floating; drifting with water currents. Periphyton - a microphyte that lives and grows on the surface of rooted aquatic plants. Benthic algae - relatively immobile algae that inhabit the submerged substrate surface of freshwater on mud, stones, or other relatively stable material. Algae may be single celled such as diatoms or Desmids, or multi-celled such as Spirogyra or Cladophora. A few such as some of the diatoms have limited abilities to move over their substrate.

=== Types === The conditions included under the term "congenital myopathy" can vary. One source includes nemaline myopathy, myotubular myopathy, central core myopathy, congenital fiber type disproportion, and multicore myopathy. The term can also be used more broadly, to describe conditions present from birth.

=== Fall in Lynn === Mrs. Mary Patterson, of Swampscott, fell upon the ice near the corner of Market and Oxford streets, on Thursday evening, and was severely injured. She was taken up in an insensible condition and carried into the residence of S. M. Bubier, Esq., near by, where she was kindly cared for during the night. Dr. Cushing, who was called, found her injuries to be internal, and of a severe nature, inducing spasms and internal suffering. She was removed to her home in Swampscott yesterday afternoon, though in a very critical condition.

Lobeline is a piperidine alkaloid found in a variety of plants, particularly those in the genus Lobelia, including Indian tobacco (Lobelia inflata), Devil's tobacco (Lobelia tupa), great lobelia (Lobelia siphilitica), Lobelia chinensis, and Hippobroma longiflora. In its pure form, it is a white amorphous powder which is freely soluble in water.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.

How does SR9009 differ from typical receptor agonists?

REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.

Has SR9009 been tested in humans?

Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.

How is SR9009 measured?

Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.

Network